1.10
price down icon20.29%   -0.28
after-market After Hours: 1.12 0.02 +1.82%
loading
Bioxcel Therapeutics Inc stock is traded at $1.10, with a volume of 4.05M. It is down -20.29% in the last 24 hours and down -0.45% over the past month. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$1.38
Open:
$1.35
24h Volume:
4.05M
Relative Volume:
5.10
Market Cap:
$33.97M
Revenue:
$680.00K
Net Income/Loss:
$-75.33M
P/E Ratio:
-0.1777
EPS:
-6.1898
Net Cash Flow:
$-57.38M
1W Performance:
-21.43%
1M Performance:
-0.45%
6M Performance:
-36.78%
1Y Performance:
-43.01%
1-Day Range:
Value
$1.10
$1.35
1-Week Range:
Value
$1.10
$1.425
52-Week Range:
Value
$1.01
$8.08

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name
Name
Bioxcel Therapeutics Inc
Name
Phone
203-643-8060
Name
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Name
Employee
29
Name
Twitter
@bioxcel_tx
Name
Next Earnings Date
2026-08-11
Name
Latest SEC Filings
Name
BTAI's Discussions on Twitter

Compare BTAI vs TAK, HLN, TEVA, ZTS, UTHR

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
BTAI icon
BTAI
Bioxcel Therapeutics Inc
1.10 43.54M 680.00K -75.33M -57.38M -6.1898
TAK icon
TAK
Takeda Pharmaceutical Co Adr
16.89 50.65B 29.91B 1.30B 3.49B 0.4056
HLN icon
HLN
Haleon Plc Adr
9.72 41.09B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
35.29 39.45B 17.53B 1.58B 444.18M 1.3457
ZTS icon
ZTS
Zoetis Inc
75.42 30.13B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
547.25 23.00B 3.17B 1.29B 1.01B 27.09

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-17-26 Initiated Rodman & Renshaw Buy
Feb-21-24 Downgrade UBS Buy → Neutral
Aug-15-23 Downgrade Mizuho Buy → Neutral
Jul-17-23 Downgrade Guggenheim Buy → Neutral
Mar-10-23 Downgrade Jefferies Buy → Hold
Dec-01-22 Upgrade Goldman Sell → Neutral
Jul-07-22 Initiated Mizuho Buy
Apr-06-22 Reiterated BofA Securities Buy
Nov-15-21 Downgrade Goldman Neutral → Sell
Apr-09-21 Initiated Berenberg Buy
Feb-01-21 Initiated UBS Buy
Oct-30-20 Initiated Goldman Buy
Sep-02-20 Initiated Jefferies Buy
Aug-17-20 Reiterated H.C. Wainwright Buy
Jul-08-20 Reiterated H.C. Wainwright Buy
Jun-04-20 Initiated Guggenheim Buy
Apr-01-20 Initiated BofA/Merrill Buy
Feb-26-20 Reiterated H.C. Wainwright Buy
Jan-08-20 Reiterated H.C. Wainwright Buy
Nov-12-19 Initiated SunTrust Buy
View All

Bioxcel Therapeutics Inc Stock (BTAI) Latest News

pulisher
Jul 01, 2026

Price to sales forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView

Jul 01, 2026
pulisher
Jun 30, 2026

BTAI Stock Gained 5% TodayWhat's The Latest On Its Opioid Withdrawal Treatment? - Stocktwits

Jun 30, 2026
pulisher
Jun 29, 2026

Price to sales forward of BioXcel Therapeutics, Inc. – MUN:BX20 - TradingView

Jun 29, 2026
pulisher
Jun 29, 2026

BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 28, 2026

BioXcel Therapeutics, Inc.(NasdaqCM:BTAI) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026
pulisher
Jun 28, 2026

Price to book forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView

Jun 28, 2026
pulisher
Jun 27, 2026

Price to earnings forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Enterprise value to revenue forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Enterprise value to EBITDA forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI - TradingView

Jun 27, 2026
pulisher
Jun 26, 2026

BioXcel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Yocca Frank - Moomoo

Jun 26, 2026
pulisher
Jun 26, 2026

BioXcel Therapeutics, Inc. Actuals & Estimates (FWB:BX20) - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

BTAI Should I Buy - Intellectia AI

Jun 26, 2026
pulisher
Jun 26, 2026

BioXcel Therapeutics, Inc. Actuals & Estimates (NASDAQ:BTAI) - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

BioXcel Therapeutics, Inc. Actuals & Estimates (LSX:A40YSR) - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

BTAI Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

BioXcel Therapeutics Inc. (BTAI) Q1 2026 Earnings: Surprise EPS Beat Drives Stock RallyEarnings Per Share - dars.gov.et

Jun 25, 2026
pulisher
Jun 23, 2026

BioXcel Therapeutics Q1 2026 Earnings: EPS Beat Driven by Cost Controls Despite No RevenuePost-Announcement Reaction - Město Břeclav

Jun 23, 2026
pulisher
Jun 23, 2026

BioXcel Therapeutics Inc (BTAI) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 23, 2026
pulisher
Jun 20, 2026

BTAI Q1 2026 Earnings: EPS Beat Amid No Revenue; Stock Edges UpEarnings Growth Analysis - dars.gov.et

Jun 20, 2026
pulisher
Jun 18, 2026

BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill

Jun 18, 2026
pulisher
Jun 17, 2026

BioXcel Therapeutics (NASDAQ: BTAI) officer converts RSUs into Common Stock - Stock Titan

Jun 17, 2026
pulisher
Jun 17, 2026

BioXcel (BTAI) CEO exercises 219 RSUs and reports major indirect stakes - Stock Titan

Jun 17, 2026
pulisher
Jun 17, 2026

BioXcel Therapeutics (BTAI) CSO converts 35 RSUs, now holds 26,210 shares - Stock Titan

Jun 17, 2026
pulisher
Jun 17, 2026

BioXcel (BTAI) CFO gains 35 shares as 212 RSUs remain - Stock Titan

Jun 17, 2026
pulisher
Jun 17, 2026

BioXcel Therapeutics Inc (BTAI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

BioXcel Therapeutics Inc (BTAI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

BioXcel Therapeutics Inc (BTAI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

BioXcel Therapeutics Inc (BTAI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

BioXcel Therapeutics Inc (BTAI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

BioXcel Therapeutics Inc (BTAI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

BioXcel Therapeutics Inc (BTAI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

BioXcel Therapeutics Inc (BTAI) Institutional Confidence - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

BioXcel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Steinhart Richard I - Moomoo

Jun 17, 2026
pulisher
Jun 05, 2026

Attention BioXcel Shareholders: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed against BioXcel Therapeutics, Inc. (BTAI) and Encourages Investors to Contact the Firm - TMX Newsfile

Jun 05, 2026
pulisher
Jun 03, 2026

What makes BioXcel Therapeutics (BTAI) a new buy stock - MSN

Jun 03, 2026
pulisher
Jun 02, 2026

BioXcel Deadline Alert - TMX Newsfile

Jun 02, 2026
pulisher
Jun 02, 2026

What Makes BioXcel Therapeutics (BTAI) a New Buy Stock - Yahoo Finance

Jun 02, 2026
pulisher
Jun 02, 2026

BioXcel Shareholder Action Reminder - TMX Newsfile

Jun 02, 2026
pulisher
May 29, 2026

BTAI Technical Analysis & Stock Price Forecast - Intellectia AI

May 29, 2026
pulisher
May 28, 2026

BioXcel presents data on at-home agitation treatment trial By Investing.com - Investing.com India

May 28, 2026
pulisher
May 28, 2026

BioXcel Therapeutics Presents New Data from Serenity At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia - marketscreener.com

May 28, 2026
pulisher
May 28, 2026

BioXcel presents data on at-home agitation treatment trial - Investing.com

May 28, 2026
pulisher
May 28, 2026

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting - The Manila Times

May 28, 2026
pulisher
May 28, 2026

BioXcel Therapeutics Presents New Data from SERENITY - GlobeNewswire

May 28, 2026
pulisher
May 28, 2026

At-home bipolar and schizophrenia agitation drug cuts symptoms in Phase 3 - Stock Titan

May 28, 2026
pulisher
May 27, 2026

BioXcel Therapeutics | 424B5: Prospectus - Moomoo

May 27, 2026
pulisher
May 27, 2026

BioXcel Therapeutics Company Profile & Introduction - Moomoo

May 27, 2026
pulisher
May 26, 2026

BTAIBioXcel Therapeutics Inc Stock Price and Quote - Finviz

May 26, 2026
pulisher
May 23, 2026

BioXcel Therapeutics CEO Mehta sells $21,108 in company stock By Investing.com - Investing.com Nigeria

May 23, 2026

Bioxcel Therapeutics Inc Stock (BTAI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Bioxcel Therapeutics Inc Stock (BTAI) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Rodriguez Javier
See Remarks
May 20 '26
Sale
1.08
6,560
7,111
26,803
Steinhart Richard I
Chief Financial Officer
May 20 '26
Sale
1.08
6,845
7,427
26,300
Mehta Vimal
CEO and President
May 20 '26
Sale
1.09
19,419
21,108
69,598
$55.14
price up icon 1.03%
RDY RDY
$14.36
price down icon 0.14%
$25.13
price up icon 0.52%
$174.10
price down icon 0.09%
$16.80
price up icon 0.60%
$547.25
price down icon 1.56%
Cap:     |  Volume (24h):